Case Report
Ectopic Axillary Breast during Systemic Lupus

Besma Ben Dhaou, Fatma Boussema, Zohra Aydi, Lilia Baili, and Lilia Rokbani
Internal Medicine Department of Habib, Thameur Hospital, Tunis 1008, Tunisia
Correspondence should be addressed to Besma Ben Dhaou, besma_2@yahoo.fr
Received 16 June 2012; Revised 9 July 2012; Accepted 11 July 2012

Copyright © 2012 Besma Ben Dhaou et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Many breast changes may occur in systemic lupus erythematosus. We report a 41-year-old woman with lupus who presented three years after the onset of lupus an ectopic mammary gland confirmed by histological study.

1. Introduction
The interruption of the migration of the milk ducts of the axilla to the midclavicular line can occur in a 2% to 6% of female embryos resulting in ectopic breast tissue. This gland undergoes the same physiological and pathological influences as the normal breast tissue. The systemic lupus erythematosus (SLE) seems to influence the mammary gland in fact several cases of mastitis, breast tumor benign or malignant were reported in patients with SLE. In this regard, we report the observation of a patient who developed a supernumerary in the course of SLE.

2. Case Report
A 41-year-old woman was admitted, in 2005, for exploration of a left axillary mass. She is followed since 2002 for SLE diagnosed at 8 ACR criteria. In 2003, the SLE was complicated by glomerular nephropathy with pure mesangial alterations and diffuse membranous glomerulonephritis so grade II and V of the WHO. The patient was then treated with corticosteroids at a dose of 1 mg/kg/day with usual degression associated with synthetic antimalarial treatment, with a favorable outcome without relapsing for two years. The examination on admission showed a patient in good general condition, cushingoid facies, and left axillary swollen, soft, 2x3 cm without signs of inflammation (Figure 1).

The lymph nodes were free. Breast examinations found no palpable nodule or nipple discharge. The ultrasound exploration of the mass showed an aspect compatible with ectopic mammary gland. The patient received a resection of this mass. Histological examination confirmed the existence of a supernumerary breast (Figure 2). Seven-year followup, so to 2012, shows a stable condition without recurrence of the mass.

3. Discussion
The originality of our observation lies in the fact that the ectopic breast was misunderstood and that it has developed after the lupus disease. Several observations have reported hypertrophy of the mammary gland in systemic lupus. It has been reported that majority of the cases of mammary hypertrophy occur during either pregnancy or puberty, supporting the theory of abnormal stimulation of mammary tissue by circulating hormones [1]. Substantial evidence of the immunoregulatory function of estradiol, testosterone, progesterone, DHEA, and pituitary hormones, including PRL, has supported the hypothesis that they modulate the incidence and severity of SLE [2, 3].

Oestrogen stimulates CD8+ and CD4+ Tcells, Bcells, macrophages, the release of certain cytokines, and the expression of both HLA and endothelial cell adhesion molecules. Another potentially important effect of estradiol may be its ability to reduce apoptosis in self-reactive Bcells, thus promoting selective maturation of B-cells with high affinity for anti-DNA [4].

Progesterone and PRL also affect immune activity. Progesterone downregulates T-cell proliferation, while lupus flares have been associated with hyperprolactinaemia [5, 6].
Elevated serum PRL levels have been reported in patients with SLE, and hyperprolactinaemia occurs in approximately 15–31% of patients with SLE, and these elevated PRL levels do appear to correlate with clinical disease activity, as well as antinuclear antibody and anti-dsDNA titreS [7–9]. Chuang and Molitch [10] noted that differences in peripheral PRL or lymphocyte production, rather than pituitary production of PRL, may worsen disease activity and breast tissue hypersensitivity. In our case, very likely ectopic axillary breast was embryologic remnant, but hypertrophy has occurred after the onset of systemic lupus.

Duffy et al. reported the case of a patient aged 24 who developed breast gigantism in a course of the lupus disease [11]. Similarly another case of refractory gynecomastia to tamoxifen has been reported requiring the use of a surgical resection [12]. Borges da Silva reported the occurrence of a hamartoma in an unknown axillary 4 mammary gland in a patient with systemic lupus [13]. Recent studies have shown an increased risk of breast cancer compared to a female population of same age [14]. Breast changes in systemic lupus are related to estrogen hyperstimulation, hyperprolactinaemia, and elevated IGF1.

4. Conclusion

Many breast changes may occur in SLE. The fact remains that before any changes in the mammary gland in a patient with lupus a biopsy must be done and because, as evidenced by the literature review, lupus is a risk factor for benign breast tumors but also and especially malignant tumors.

References

[1] A. E. Lanzon and S. V. Navarra, “Gigantomastia in a patient with systemic lupus erythematosus successfully treated by reduction mammoplasty,” Lupus, vol. 18, no. 14, pp. 1309–1312, 2009.

[2] R. W. McMurray and W. May, “Sex hormones and systemic lupus erythematosus: review and meta-analysis,” Arthritis and Rheumatism, vol. 48, no. 8, pp. 2100–2110, 2003.
[3] J. Li, W. May, and R. W. McMurray, “Pituitary hormones and systemic lupus erythematosus,” *Arthritis and Rheumatism*, vol. 52, no. 12, pp. 3701–3712, 2005.

[4] J. F. G. Cohen-Solal, V. Jeganathan, C. M. Grimaldi, E. Phee, and B. Diamond, “Sex hormones and SLE: influencing the fate of autoreactive B Cells,” *Current Topics in Microbiology and Immunology*, vol. 305, pp. 67–88, 2006.

[5] L. E. Clemens, P. K. Siiteri, and D. P. Stites, “Mechanism of immunosuppression of progesterone on maternal lymphocyte activation during pregnancy,” *Journal of Immunology*, vol. 122, no. 5, pp. 1978–1985, 1979.

[6] D. Buskila, S. Sukenik, and Y. Shoenfeld, “The possible role of prolactin in autoimmunity,” *American Journal of Reproductive Immunology*, vol. 26, no. 3, pp. 118–123, 1991.

[7] F. Blanco-Favela, G. Quintal-Alvarez, and A. Leaños-Miranda, “Association between prolactin and disease activity in systemic lupus erythematosus. Influence of statistical power,” *Journal of Rheumatology*, vol. 26, no. 1, pp. 55–59, 1999.

[8] A. M. Jacobi, W. Rohde, M. Ventz, G. Riemekasten, G. R. Burmester, and F. Hiepe, “Enhanced serum prolactin (PRL) in patients with systemic lupus erythematosus: PRL levels are related to the disease activity,” *Lupus*, vol. 10, no. 8, pp. 554–561, 2001.

[9] M. Pacilio, S. Migliaresi, R. Meli, L. Ambrosone, B. Bigliardo, and R. Di Carlo, “Elevated bioactive prolactin levels in systemic lupus erythematosus—association with disease activity,” *Journal of Rheumatology*, vol. 28, no. 10, pp. 2216–2221, 2001.

[10] E. Chuang and M. Molitch, “Prolactin and autoimmune diseases in women,” *Acta BioMedica*, vol. 78, no. 11, pp. 255–261, 2007.

[11] D. A. Duffy, M. L. Demers, and M. R. Molin, “Systemic lupus erythematosus with breast gigantism,” *Journal of Rheumatology*, vol. 22, no. 6, pp. 1214–1215, 1995.

[12] D. Kulkarni, N. Beechey-Newman, H. Hamed, and I. S. Fentiman, “Gigantomastia: a problem of local recurrence,” *Breast*, vol. 15, no. 1, pp. 100–102, 2006.

[13] B. Borges da Silva, J. S. Rodrigues, U. S. Borges, C. G. Pires, and R. F. Pereira da Silva, “Large mammary hamartoma of axillary supernumerary breast tissue,” *Breast*, vol. 15, no. 1, pp. 135–136, 2006.

[14] R. Ramsey-Goldman, S. A. Mattai, E. Schilling et al., “Increased risk of malignancy in patients with systemic lupus erythematosus,” *Journal of Investigative Medicine*, vol. 46, no. 5, pp. 217–222, 1998.